The NSDHL/c-Myc/PKM2 Axis Drives Glycolytic Reprogramming and Tumor Growth in Multiple Myeloma
Open Access
- 16 September 2026
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (18) , 8239
Abstract
Multiple myeloma (MM) remains largely incurable because of its complex biology and frequent disease relapse. Metabolic reprogramming is increasingly recognized as a critical contributor to MM progression. NAD (P)-dependent steroid dehydrogenase-like protein (NSDHL) has been highlighted as an unfavorable metabolism-related prognostic gene in plasma cell myeloma, but its functional significance and metabolic role in MM remain unclear. Publicly available MM transcriptomic datasets and the MMRF-CoMMpass cohort were analyzed to evaluate NSDHL expression and its clinical relevance. Cell proliferation was assessed using CCK-8 assays, while glucose consumption, lactate production, and extracellular acidification rate were measured to evaluate glycolytic activity. RNA sequencing was performed following NSDHL knockdown. NSDHL was upregulated in MM and associated with advanced disease stage and poor overall survival. NSDHL knockdown suppressed MM cell proliferation and glycolytic activity. Mechanistically, NSDHL reduced c-Myc phosphorylation at T58 while promoting phosphorylation at S62, thereby inhibiting proteasome-dependent degradation of c-Myc and stabilizing the protein. Stabilized c-Myc subsequently enhanced the transcriptional expression of Pyruvate kinase M2 (PKM2), leading to increased glycolysis. Our data reveal a novel NSDHL/c-Myc/PKM2 regulatory axis that drives glycolytic reprogramming and MM cell proliferation, highlighting NSDHL as a potential prognostic biomarker and therapeutic target in MM.Keywords
Funding Information
- National Natural Science Foundation of China (82270209)
- National Natural Science Foundation of China (82470197)
- National Natural Science Foundation of China (32560161)
This publication has 37 references indexed in Scilit:
- Metabolic alterations in multiple myeloma and extramedullary disease- a novel niche of therapeutic targetsBlood Reviews, 2025
- A Review on the Role of Pyruvate Kinase M2 in Cancer: From Metabolic Switch to Transcriptional RegulationInternational Journal of Biological Macromolecules, 2025
- KIAA1429 increases FOXM1 expression through YTHDF1–mediated m6A modification to promote aerobic glycolysis and tumorigenesis in multiple myelomaCell Biology and Toxicology, 2024
- The hallmarks of cancer metabolism: Still emergingCell Metabolism, 2022
- NSDHL promotes triple-negative breast cancer metastasis through the TGFβ signaling pathway and cholesterol biosynthesisBreast Cancer Research and Treatment, 2021
- Targeting “undruggable” c-Myc protein by synthetic lethalityFrontiers of Medicine, 2021
- NAD(P)‐dependent steroid dehydrogenase‐like protein and neutral cholesterol ester hydrolase 1 serve as novel markers for early detection of gastric cancer identified using quantitative proteomicsJournal of Clinical Laboratory Analysis, 2020
- Crystal structures of human NSDHL and development of its novel inhibitor with the potential to suppress EGFR activityCellular and Molecular Life Sciences, 2020
- MYC on the Path to CancerCell, 2012
- Hallmarks of Cancer: The Next GenerationCell, 2011